Douglas Wolfe, MD
Clinical Cardiac Electrophysiology · Jackson, MSNPI 1861411621
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $2,885 and has fallen 88.5% since, to $331 in 2025.
Across 180 payments — averaging $48.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$2K
- Atricure, Inc.$2K
- Boehringer Ingelheim$549
- Novartis$444
- Pfizer$239
- plus $2K from 17 others
What the payments were for
- Travel & lodging$4,20248%
- Food & beverage$4,50752%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $2,095 |
| Boston Scientific | 15 | $1,767 |
| Atricure, Inc. | 6 | $1,622 |
| Boehringer Ingelheim | 24 | $549 |
| Novartis | 25 | $444 |
| Pfizer | 16 | $239 |
| Sanofi | 2 | $235 |
| Livanova USA, Inc. | 2 | $211 |
| Amgen | 12 | $187 |
| AstraZeneca | 8 | $184 |
| Johnson & Johnson | 12 | $183 |
| Akcea Therapeutics, Inc. | 9 | $174 |
| Merck | 4 | $166 |
| Cvrx, Inc. | 2 | $150 |
| Abbott | 5 | $147 |
| Biotronik Inc. | 2 | $135 |
| E.r. Squibb & Sons, L.L.C. | 7 | $97 |
| Gilead | 3 | $47 |
| Lundbeck LLC | 2 | $41 |
| Astellas Pharma US Inc | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical cardiac electrophysiology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 307 | $330,696 |
| EliquisApixaban | 241 | $217,703 |
| EntrestoSacubitril/Valsartan | 175 | $175,248 |
| Droxidopa | 61 | $163,136 |
| XareltoRivaroxaban | 155 | $123,869 |
| FarxigaDapagliflozin Propanediol | 146 | $109,393 |
| MultaqDronedarone Hcl | 20 | $36,635 |
| VerquvoVericiguat | 27 | $21,567 |
| BrilintaTicagrelor | 25 | $18,461 |
| WegovySemaglutide | 11 | $16,921 |
| Midodrine Hcl | 166 | $11,976 |
| Ranolazine ErRanolazine | 115 | $10,871 |
| Pyridostigmine Bromide | 148 | $8,641 |
| Repatha SureclickEvolocumab | 16 | $8,449 |
| Propafenone Hcl | 122 | $7,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $549 | $330,696307 claims |
| PfizerEliquis | $239 | $217,703241 claims |
| NovartisEntresto | $444 | $175,248175 claims |
| AstraZenecaFarxiga, Brilinta | $184 | $127,854171 claims |
| Johnson & JohnsonXarelto | $183 | $123,869155 claims |
| MerckVerquvo | $166 | $21,56727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other clinical cardiac electrophysiology in Jackson
- James Hamilton IvJackson$34K
- Jimmy LottJackson$16K
- Sandra McCearleyJackson$10K
- Joseph OwenJackson$8K
- John PayneJackson$197
- Karthik Venkatesh PrasadTupelo$86K
- James StoneTupelo$61K
- Elsheikh AbdelrahimTupelo$35K
- Attila RokaMeridian$16K
- Santo BorganelliHattiesburg$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.